RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Raw

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.9B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-44-58-106-89-360-290-410-491-761-886-858-853-1,131-440-278
Depreciation and amortization--------6173548445457
Non-Cash Interest Expense On Sale Of Future Royalties----------84117104107127
Stock-based compensation1917122133467693158175140166231222272
Realized and unrealized losses on marketable equity securities--------4115456-33-17-3
Loss on extinguishment of debt-------------77--
Change in fair value of development derivative liability---------9---95-91-171
Deferred income taxes----------2-3-3-1-1-107
Other-------1--3115800-39
Accounts receivable, net---------152456102468887
Inventory--------2332352634-18-14
Prepaid expenses and other assets3-3-21675213522-1532399-3
Accounts payable, accrued expenses and other liabilities---------92144881928191
Deferred revenue---------13392-44-50-6655-235
Net cash (used in) provided by operating activities-84-87-116-69-----563-278-615-642-541104-8
Purchases of property, plant and equipment5184913651041271407076726234
Purchases of marketable securities----9781,0347599031,1042,0762,0261,6561,9771,8241,635
Sales and maturities of marketable securities--------1,5191,7751,6921,4642,2321,5541,572
Proceeds from Sale of Restricted Investments-------120-30-42905858
Purchases of restricted investments--------15-2642985877
Other investing activities---------754540
Net cash (used in) provided by investing activities18823-131----273-418-436-273169-336-117
Proceeds from exercise of stock options and other types of equity, net31729293114846971200246259147303
Proceeds from Convertible Debt------------1,016--
Purchases of capped calls related to convertible debt------------119--
(Repayment of) proceeds from development derivative liability, net--------------9
Net cash provided by financing activities4193201----658239951,247426172294
Effect of exchange rate changes on cash, cash equivalents and restricted cash----------05-9-76-15
Net increase (decrease) in cash, cash equivalents and restricted cash---------224127-5132346-54154
Cash paid for interest--------10-25453268
Income Taxes Paid, Net611-0-01-00-------14
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability----------3481-9
Capital Expenditures Incurred but Not yet Paid--102133833151514542